Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

被引：51
|
作者：
Kang, Jin [1 ,2 ,3 ]
Chen, Hua-Jun [2 ,3 ]
Wang, Zheng [4 ]
Liu, Jing [5 ]
Li, Bing [5 ]
Zhang, Tengfei [5 ]
Yang, Zhenfan [4 ]
Wu, Yi-Long [2 ,3 ,6 ]
Yang, Jin-Ji [1 ,2 ,3 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[4] AstraZeneca, Asia Innovat Med, Shanghai, Peoples R China
[5] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1016/j.jtho.2017.10.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E49 / E53
页数：5
相关论文
共 50 条
  • [41] Radiation As a Local Ablative Therapy Option for Oligoprogressive EGFR-Mutant Non-Small Cell Lung Cancer after Treatment with Osimertinib
    Kesarwala, A. H.
    Kim, C.
    Jones, J. C.
    Kaushal, A.
    Roper, N.
    Hoang, C. D.
    Szabo, E.
    Connolly, M.
    Padiernos, E.
    Cultraro, C.
    Waris, M.
    Gao, S.
    Steinberg, S. M.
    Khan, J.
    Rajan, A.
    Guha, U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E467 - E468
  • [42] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma
    Hirata, H.
    Nakamura, K.
    Kunitake, N.
    Shioyama, Y.
    Sasaki, T.
    Nonoshita, T.
    Inoue, K.
    Nagashima, A.
    Ono, M.
    Honda, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S102 - S102
  • [43] Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma
    Stewart, Erin L.
    Mascaux, Celine
    Pham, Nhu-An
    Sakashita, Shingo
    Sykes, Jenna
    Kim, Lucia
    Yanagawa, Naoki
    Allo, Ghassan
    Ishizawa, Kota
    Wang, Dennis
    Zhu, Chang-Qi
    Li, Ming
    Ng, Christine
    Liu, Ni
    Pintilie, Melania
    Martin, Petra
    John, Tom
    Jurisica, Igor
    Leighl, Natasha B.
    Neel, Benjamin G.
    Waddell, Thomas K.
    Shepherd, Frances A.
    Liu, Geoffrey
    Tsao, Ming-Sound
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) : 2472 - U94
  • [44] Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
    Chiang, Chi-Lu
    Yeh, Yi-Chen
    Chou, Teh-Ying
    Chiu, Chao-Hua
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (09) : 1439 - 1441
  • [45] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
    Kim, Chul
    Roper, Nitin
    Hoang, Chuong D.
    Szabo, Eva
    Connolly, Maureen
    Padiernos, Emerson
    Kesarwala, Aparna Hemant
    Cultraro, Constance
    Waris, Maryam
    Gao, Shaojian
    Steinberg, Seth M.
    Wong, David T.
    Khan, Laved
    Rajan, Arun
    Guha, Udayan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
    Kim, Chul
    Roper, Nitin
    Hoang, Chuong D.
    Wisch, Laura
    Connolly, Maureen
    Chou, Hsien-Chao
    Wei, Jun S.
    Tyagi, Manoj
    Cultraro, Constance
    Xi, Liqiang
    Waris, Maryam
    Szabo, Eva
    Padiernos, Emerson
    Kesarwala, Aparna Hemant
    Gao, Shaojian
    Steinberg, Seth M.
    Raffeld, Mark
    Rajan, Arun
    Khan, Javed
    Guha, Udayan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
    Zhang, Ping
    Nie, Xin
    Wang, Bing
    Li, Lin
    THORACIC CANCER, 2018, 9 (12) : 1774 - 1777
  • [48] Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    Bean, J.
    Riely, G. J.
    Balak, M.
    Marks, J. L.
    Ladanyi, M.
    Miller, V. A.
    Pao, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy
    Zhou, Yuling
    Zeng, Liang
    Yang, Nong
    Zhang, Yongchang
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
  • [50] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
    Iams, W.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
12345